Login
Companies $RARE
$15.85 -$0.05 (0.31%) After hours
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

ultragenyx.com

What Do They Do?

Develops and sells therapies for people with serious rare and ultra-rare genetic diseases, including biologic drugs, small molecules and gene therapies.

How Do They Make Money?

Sells approved medicines through distributors, with product sales tied to delivery. It also receives royalties under license agreements as the related product sales occur.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Collaboration and license
0.0%
FY2022: 61%
Product sales
Sold outright

55%
FY2022: 33%
Royalty
Licensed

45%
FY2022: 6.0%

Who Are Their Customers?

Its customers include collaboration partners, drug wholesalers and retail pharmacy distributors; approved products are sold through a limited number of distributors. It has its own commercial organization in many markets and uses third-party distributors in smaller markets.

Customers above 10% of revenue, FY2025
of revenue from one customer

Do Revenues Turn Into Profits?

No. It lost $575M in FY2025.

Operating income, FY2025
−79% of revenue
▲ 0% (Loss) vs FY2024 (−$536M, −96%)
Net income, FY2025
−85% of revenue
▼ −1% (Loss) vs FY2024 (−$569M, −102%)
Free cash flow, FY2025
−70% of revenue
▼ −12% (Loss) vs FY2024 (−$421M, −75%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +8%
vs $160M in Q3 FY2025
Net income
▲ +34% (Loss)
vs −$180M in Q3 FY2025
Product Revenue share of revenue vs 59.4% in Q3 FY2025
  • Sep 2, 2026 Aspire Phase 3 study missed its primary and key secondary endpoints Ultragenyx will assess apazunersen’s future and plan significant expense reductions.
  • Aug 19, 2026 FDA granted accelerated approval for GENGLYCOS Approval covers adult and pediatric patients eight years and older with glycogen storage disease type Ia.
  • Aug 11, 2026 Settlement grants Esjay a license for a generic DOJOLVI Esjay may market its generic version beginning January 1, 2033, subject to conditions.
  • Aug 4, 2026 Ultragenyx reaffirmed its 2026 revenue guidance The company reaffirmed full-year revenue guidance of $730 million to $760 million.

Evkeeza's geographic reach The earlier report described Evkeeza as approved in the U.S. and European Economic Area; the latest report also lists Brazil, Mexico and Japan.

Revenue over time
Collaboration and license Product sales Royalty
$1B$500M$0

Who Do They Compete With?

Competes with Arrowhead Pharmaceuticals, Eli Lilly, Dicerna, Novo Nordisk, CRISPR Therapeutics, Ionis, Oak Hill Bio, Neuren Pharmaceuticals, MavriX Bio, Esteve, Orchard Therapeutics, Denali, JCR Pharma, GC Biopharma, Novel Pharma, Beam Therapeutics, Moderna, Acer Therapeutics, Arcturus Therapeutics, and Bloomsbury

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support